PL3735299T3 - Związki o pierścieniach skondensowanych - Google Patents
Związki o pierścieniach skondensowanychInfo
- Publication number
- PL3735299T3 PL3735299T3 PL19842848.4T PL19842848T PL3735299T3 PL 3735299 T3 PL3735299 T3 PL 3735299T3 PL 19842848 T PL19842848 T PL 19842848T PL 3735299 T3 PL3735299 T3 PL 3735299T3
- Authority
- PL
- Poland
- Prior art keywords
- fused ring
- ring compounds
- compounds
- fused
- ring
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Physiology (AREA)
- Dermatology (AREA)
- Nutrition Science (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2018114788 | 2018-11-09 | ||
| PCT/US2019/060578 WO2020097537A2 (en) | 2018-11-09 | 2019-11-08 | Fused ring compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3735299T3 true PL3735299T3 (pl) | 2025-01-27 |
Family
ID=69232886
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL19842848.4T PL3735299T3 (pl) | 2018-11-09 | 2019-11-08 | Związki o pierścieniach skondensowanych |
Country Status (33)
| Country | Link |
|---|---|
| US (3) | US11236068B2 (pl) |
| EP (2) | EP3735299B1 (pl) |
| JP (4) | JP6941241B2 (pl) |
| KR (3) | KR20250012188A (pl) |
| CN (5) | CN112105419B (pl) |
| AR (1) | AR117194A1 (pl) |
| AU (3) | AU2019377130B2 (pl) |
| BR (1) | BR112021008986A2 (pl) |
| CA (1) | CA3087089C (pl) |
| CL (2) | CL2021001171A1 (pl) |
| CO (1) | CO2021005987A2 (pl) |
| CR (1) | CR20210229A (pl) |
| DK (1) | DK3735299T3 (pl) |
| ES (1) | ES3004042T3 (pl) |
| FI (1) | FI3735299T3 (pl) |
| HR (1) | HRP20241581T1 (pl) |
| HU (1) | HUE069365T2 (pl) |
| IL (3) | IL311187B1 (pl) |
| LT (1) | LT3735299T (pl) |
| MA (1) | MA51530B1 (pl) |
| MX (5) | MX2021005428A (pl) |
| MY (1) | MY196726A (pl) |
| PE (2) | PE20211504A1 (pl) |
| PH (1) | PH12021551065A1 (pl) |
| PL (1) | PL3735299T3 (pl) |
| PT (1) | PT3735299T (pl) |
| RS (1) | RS66280B1 (pl) |
| SG (1) | SG11202103298QA (pl) |
| SI (1) | SI3735299T1 (pl) |
| SM (1) | SMT202400487T1 (pl) |
| TW (2) | TWI883352B (pl) |
| UA (1) | UA127930C2 (pl) |
| WO (1) | WO2020097537A2 (pl) |
Families Citing this family (89)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112020020307A2 (pt) | 2018-04-04 | 2021-01-12 | Arvinas Operations, Inc. | Moduladores de proteólise e métodos de uso associados |
| JP7451419B2 (ja) | 2018-10-26 | 2024-03-18 | 大鵬薬品工業株式会社 | 新規なインダゾール化合物又はその塩 |
| AU2020279287B2 (en) | 2019-05-21 | 2025-11-27 | InventisBio Co., Ltd. | Heterocyclic compounds, preparation methods and uses thereof |
| US12122787B2 (en) | 2019-09-20 | 2024-10-22 | Shanghai Jemincare Pharmaceuticals Co., Ltd | Fused pyridone compound, and preparation method therefor and use thereof |
| CR20220230A (es) | 2019-10-28 | 2022-06-15 | Merck Sharp & Dohme | Inhibidores de pequeñas moléculas de mutante g12c de kras |
| WO2021108683A1 (en) | 2019-11-27 | 2021-06-03 | Revolution Medicines, Inc. | Covalent ras inhibitors and uses thereof |
| EP4067343A4 (en) | 2019-11-29 | 2024-01-03 | Taiho Pharmaceutical Co., Ltd. | NEW PHENOLIC COMPOUND OR SALT THEREOF |
| WO2021120045A1 (en) | 2019-12-18 | 2021-06-24 | InventisBio Co., Ltd. | Heterocyclic compounds, preparation methods and uses thereof |
| US12441707B2 (en) | 2019-12-30 | 2025-10-14 | Tyra Biosciences, Inc. | Indazole compounds |
| CA3183032A1 (en) | 2020-06-18 | 2021-12-23 | Mallika Singh | Methods for delaying, preventing, and treating acquired resistance to ras inhibitors |
| TWI829003B (zh) * | 2020-08-12 | 2024-01-11 | 美商建南德克公司 | 喹唑啉化合物之合成 |
| US20230391779A1 (en) * | 2020-08-17 | 2023-12-07 | Betta Pharmaceuticals Co., Ltd. | Bicyclic compounds, compositions and use thereof |
| EP4203952A4 (en) | 2020-08-28 | 2024-12-11 | Kumquat Biosciences Inc. | HETEROCYCLIC COMPOUNDS AND USES THEREOF |
| MX2023002248A (es) | 2020-09-03 | 2023-05-16 | Revolution Medicines Inc | Uso de inhibidores de sos1 para tratar neoplasias malignas con mutaciones de shp2. |
| AU2021340716A1 (en) | 2020-09-11 | 2023-03-30 | Mirati Therapeutics, Inc. | Crystalline forms of a KRas G12C inhibitor |
| US12162893B2 (en) | 2020-09-23 | 2024-12-10 | Erasca, Inc. | Tricyclic pyridones and pyrimidones |
| US20230365563A1 (en) * | 2020-09-30 | 2023-11-16 | Shanghai Pharmaceuticals Holding Co., Ltd. | Quinazoline compound and application thereof |
| US20240034733A1 (en) * | 2020-11-03 | 2024-02-01 | Mirati Therapeutics, Inc. | Kras g12d inhibitors |
| CN116568305A (zh) * | 2020-11-13 | 2023-08-08 | 基因泰克公司 | 用于治疗肺癌的方法以及包含krasg12c抑制剂和pd-l1结合拮抗剂的组合物 |
| JP2023550028A (ja) * | 2020-11-13 | 2023-11-30 | ジェネンテック， インコーポレイテッド | 固形腫瘍を治療するためのｋｒａｓｇ１２ｃ阻害剤及びｖｅｇｆ阻害剤を含む方法及び組成物 |
| WO2022105855A1 (en) * | 2020-11-20 | 2022-05-27 | Jacobio Pharmaceuticals Co., Ltd. | Kras g12d inhibitors |
| TW202229285A (zh) * | 2020-11-20 | 2022-08-01 | 大陸商北京加科思新藥研發有限公司 | Kras g12d抑制劑 |
| JP7637777B2 (ja) * | 2020-12-08 | 2025-02-28 | ジェネンテック， インコーポレイテッド | 固形腫瘍を治療するためのｋｒａｓｇ１２ｃ阻害剤及びｅｇｆｒ阻害剤を含む方法及び組成物 |
| AU2021401232A1 (en) | 2020-12-15 | 2023-06-22 | Mirati Therapeutics, Inc. | Azaquinazoline pan-kras inhibitors |
| US11999753B2 (en) | 2020-12-16 | 2024-06-04 | Mirati Therapeutics, Inc. | Tetrahydropyridopyrimidine pan-KRas inhibitors |
| CN113999226B (zh) * | 2020-12-22 | 2023-01-06 | 上海科州药物研发有限公司 | 作为kras抑制剂的杂环化合物的制备及其应用方法 |
| EP4269405A4 (en) * | 2020-12-22 | 2024-07-24 | Shanghai Kechow Pharma, Inc. | Preparation and application method of heterocyclic compound as kras inhibitor |
| CN114685532A (zh) * | 2020-12-31 | 2022-07-01 | 正大天晴药业集团股份有限公司 | 大环类化合物及其医药用途 |
| JP2024506329A (ja) * | 2021-02-09 | 2024-02-13 | カムクワット バイオサイエンシーズ インコーポレイテッド | 複素環式化合物およびその使用 |
| WO2022171013A1 (zh) * | 2021-02-09 | 2022-08-18 | 南京明德新药研发有限公司 | 四氢喹唑啉类化合物 |
| TWI824405B (zh) * | 2021-02-09 | 2023-12-01 | 美商建南德克公司 | 四環氧氮呯化合物及其用途 |
| WO2022171018A1 (zh) * | 2021-02-09 | 2022-08-18 | 苏州泽璟生物制药股份有限公司 | 取代苯并或吡啶并嘧啶胺类抑制剂及其制备方法和应用 |
| CA3209083A1 (en) * | 2021-02-16 | 2022-08-25 | Theras, Inc. | Compositions and methods for inhibition of ras |
| WO2022214102A1 (zh) * | 2021-04-09 | 2022-10-13 | 杭州英创医药科技有限公司 | 作为kras g12d抑制剂的杂环化合物 |
| WO2022221386A1 (en) * | 2021-04-14 | 2022-10-20 | Erasca, Inc. | Selective kras inhibitors |
| EP4322954A4 (en) * | 2021-04-16 | 2025-01-29 | Merck Sharp & Dohme LLC | SMALL MOLECULAR INHIBITORS OF THE KRAS G12D MUTANT |
| MX2023012726A (es) * | 2021-04-29 | 2024-01-04 | Amgen Inc | Compuestos heterociclicos y metodos de uso. |
| WO2022235866A1 (en) * | 2021-05-05 | 2022-11-10 | Revolution Medicines, Inc. | Covalent ras inhibitors and uses thereof |
| EP4340883A1 (en) * | 2021-05-19 | 2024-03-27 | Genentech, Inc. | Combination therapy |
| US20240300980A1 (en) * | 2021-05-22 | 2024-09-12 | Shanghai Kechow Pharma, Inc. | Heterocyclic compounds as kras inhibitor, and preparation therefor and use thereof in treatment |
| WO2022251496A1 (en) * | 2021-05-26 | 2022-12-01 | Cornell University | Rigidified macrocycles, complexes with radionuclides, and use in targeted radiotherapy of cancer |
| IL310291A (en) | 2021-07-23 | 2024-03-01 | Theras Inc | Compositions and methods for inhibition of ras |
| WO2023020518A1 (en) * | 2021-08-18 | 2023-02-23 | Jacobio Pharmaceuticals Co., Ltd. | N-cyclopropylpyrido [4, 3-d] pyrimidin-4-amine derivatives and uses thereof |
| TW202315626A (zh) * | 2021-08-31 | 2023-04-16 | 大陸商勁方醫藥科技(上海)有限公司 | 嘧啶并環類化合物及其製法和用途 |
| TW202327569A (zh) | 2021-09-01 | 2023-07-16 | 瑞士商諾華公司 | 包含ｔｅａｄ抑制劑的藥物組合及其用於癌症治療之用途 |
| JP2024541508A (ja) | 2021-11-24 | 2024-11-08 | ジェネンテック， インコーポレイテッド | 治療用インダゾール化合物およびがんの治療における使用方法 |
| US12275745B2 (en) | 2021-11-24 | 2025-04-15 | Genentech, Inc. | Therapeutic compounds and methods of use |
| WO2023097227A1 (en) * | 2021-11-24 | 2023-06-01 | Merck Sharp & Dohme Llc | Small molecule inhibitors of kras mutated proteins |
| CA3240772A1 (en) | 2021-12-22 | 2023-06-29 | Kevan M. Shokat | Covalently binding inhibitors of g12s, g12d and/or g12e mutants of k-ras gtpase |
| US20250188085A1 (en) * | 2022-01-06 | 2025-06-12 | Theras, Inc. | Compositions and methods for inhibition of ras |
| US20250084079A1 (en) * | 2022-01-06 | 2025-03-13 | Theras, Inc. | Compositions and methods for inhibition of ras |
| MX2024009215A (es) * | 2022-02-07 | 2024-08-30 | Hoffmann La Roche | Proceso para la sintesis de compuestos de quinazolina. |
| MX2024009593A (es) | 2022-02-07 | 2024-08-14 | Genentech Inc | Formas solidas de 1-((s)-4-((r)-7-(6-amino-4-metil-3-(trifluoromet il)piridin-2-il)-6-cloro-8-fluoro-2-(((s)-1-metilpirrolidin-2-il) metoxi)quinazolin-4-il)-3-metilpiperazin-1-il)prop-2-en-1-ona. |
| JP2025508133A (ja) | 2022-03-11 | 2025-03-21 | カムクワット バイオサイエンシーズ インコーポレイテッド | 複素環式化合物およびその使用 |
| WO2023190748A1 (ja) | 2022-03-31 | 2023-10-05 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 腫瘍治療用医薬組成物 |
| EP4504202B1 (en) * | 2022-04-06 | 2026-02-04 | Genentech Inc. | Combination therapies comprising gdc-6036 and gdc-0077 for the treatment of cancer |
| AU2023272945A1 (en) | 2022-05-19 | 2024-11-07 | Genentech, Inc. | Aza-tetracyclic oxazepine compounds and uses thereof |
| CN115043729B (zh) * | 2022-07-04 | 2024-09-27 | 青岛大学 | 一种2,2’-二氟联芳基化合物的不对称合成方法 |
| WO2024031088A1 (en) | 2022-08-05 | 2024-02-08 | Kumquat Biosciences Inc. | Heterocyclic compounds and uses thereof |
| CN119677726A (zh) | 2022-08-11 | 2025-03-21 | 百时美施贵宝公司 | Kras抑制剂 |
| WO2024040131A1 (en) | 2022-08-17 | 2024-02-22 | Treeline Biosciences, Inc. | Pyridopyrimidine kras inhibitors |
| WO2024081674A1 (en) | 2022-10-11 | 2024-04-18 | Aadi Bioscience, Inc. | Combination therapies for the treatment of cancer |
| PE20252384A1 (es) | 2022-11-21 | 2025-10-10 | Treeline Biosciences Inc | Inhibidores espirociclicos de kras basados en dihidropiranopirimidina |
| CN115920658B (zh) * | 2023-01-15 | 2023-10-20 | 安徽科博瑞环境科技有限公司 | 低表面能抗污染中空纤维膜及其制备方法 |
| WO2024153119A1 (en) * | 2023-01-18 | 2024-07-25 | Suzhou Zanrong Pharma Limited | Kras g12d inhibitors and uses thereof |
| EP4655298A1 (en) * | 2023-01-24 | 2025-12-03 | Theras Inc. | Compositions and methods for inhibition of ras |
| AU2024212035A1 (en) | 2023-01-26 | 2025-08-14 | Arvinas Operations, Inc. | Cereblon-based kras degrading protacs ans uses related thereto |
| AU2024241633A1 (en) | 2023-03-30 | 2025-11-06 | Revolution Medicines, Inc. | Compositions for inducing ras gtp hydrolysis and uses thereof |
| AU2023439518A1 (en) | 2023-04-06 | 2025-08-28 | Eisai R&D Management Co., Ltd. | Pharmaceutical composition for treating tumors |
| CN116396202A (zh) * | 2023-04-17 | 2023-07-07 | 南京优氟医药科技有限公司 | 一种（2s，4s）-4-氟代吡咯烷-2-羧酸的制备方法 |
| WO2024229406A1 (en) | 2023-05-04 | 2024-11-07 | Revolution Medicines, Inc. | Combination therapy for a ras related disease or disorder |
| US20250000802A1 (en) | 2023-06-09 | 2025-01-02 | Hoffmann-La Roche Inc. | Solid formulations comprising an inhibitor of the k-ras protein having a g12c mutation, and a process for preparing |
| WO2025010415A1 (en) * | 2023-07-05 | 2025-01-09 | The Regents Of The University Of California | Gtpase inhibitors and uses thereof |
| US20250049810A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025064848A1 (en) | 2023-09-21 | 2025-03-27 | Treeline Biosciences, Inc. | Spirocyclic dihydropyranopyridine kras inhibitors |
| TW202529768A (zh) | 2023-09-29 | 2025-08-01 | 大陸商德昇濟醫藥（無錫）有限公司 | 癌症治療的療法 |
| TW202530228A (zh) | 2023-10-12 | 2025-08-01 | 美商銳新醫藥公司 | Ｒａｓ抑制劑 |
| TW202535891A (zh) | 2023-10-20 | 2025-09-16 | 美商默沙東有限責任公司 | Ｋｒａｓ蛋白之小分子抑制劑 |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| TW202547461A (zh) | 2024-05-17 | 2025-12-16 | 美商銳新醫藥公司 | Ｒａｓ抑制劑 |
| WO2025245127A1 (en) | 2024-05-21 | 2025-11-27 | Treeline Biosciences, Inc. | Spirocyclic dihydropyranopyrimidine kras inhibitors |
| WO2025255438A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1999002557A1 (en) | 1997-07-11 | 1999-01-21 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V | Novel pharmaceutically active compounds interacting with gtp-binding proteins |
| RU2560153C2 (ru) | 2008-06-20 | 2015-08-20 | Дженентек, Инк. | Триазолпиридиновые соединения, ингибирующие jak, и способы |
| CN104379563B (zh) | 2012-04-10 | 2018-12-21 | 加利福尼亚大学董事会 | 用于治疗癌症的组合物和方法 |
| JO3805B1 (ar) | 2013-10-10 | 2021-01-31 | Araxes Pharma Llc | مثبطات كراس جي12سي |
| EP3636639A1 (en) * | 2013-10-10 | 2020-04-15 | Araxes Pharma LLC | Inhibitors of kras g12c |
| JO3556B1 (ar) | 2014-09-18 | 2020-07-05 | Araxes Pharma Llc | علاجات مدمجة لمعالجة السرطان |
| WO2016049568A1 (en) | 2014-09-25 | 2016-03-31 | Araxes Pharma Llc | Methods and compositions for inhibition of ras |
| JP2017528498A (ja) | 2014-09-25 | 2017-09-28 | アラクセス ファーマ エルエルシー | Ｋｒａｓ ｇ１２ｃ変異体タンパク質のインヒビター |
| ES2898765T3 (es) | 2015-04-10 | 2022-03-08 | Araxes Pharma Llc | Compuestos de quinazolina sustituidos y métodos de uso de los mismos |
| US10144724B2 (en) | 2015-07-22 | 2018-12-04 | Araxes Pharma Llc | Substituted quinazoline compounds and methods of use thereof |
| WO2017070256A2 (en) | 2015-10-19 | 2017-04-27 | Araxes Pharma Llc | Method for screening inhibitors of ras |
| US10414757B2 (en) | 2015-11-16 | 2019-09-17 | Araxes Pharma Llc | 2-substituted quinazoline compounds comprising a substituted heterocyclic group and methods of use thereof |
| US9988357B2 (en) | 2015-12-09 | 2018-06-05 | Araxes Pharma Llc | Methods for preparation of quinazoline derivatives |
| WO2017172979A1 (en) | 2016-03-30 | 2017-10-05 | Araxes Pharma Llc | Substituted quinazoline compounds and methods of use |
| SG11201810171SA (en) * | 2016-05-18 | 2018-12-28 | Mirati Therapeutics Inc | Kras g12c inhibitors |
| US10646488B2 (en) | 2016-07-13 | 2020-05-12 | Araxes Pharma Llc | Conjugates of cereblon binding compounds and G12C mutant KRAS, HRAS or NRAS protein modulating compounds and methods of use thereof |
| KR20200010306A (ko) | 2017-05-25 | 2020-01-30 | 아락세스 파마 엘엘씨 | Kras의 공유적 억제제 |
| WO2018218069A1 (en) | 2017-05-25 | 2018-11-29 | Araxes Pharma Llc | Quinazoline derivatives as modulators of mutant kras, hras or nras |
| CN110869357A (zh) | 2017-05-25 | 2020-03-06 | 亚瑞克西斯制药公司 | 化合物及其用于治疗癌症的使用方法 |
| PT3710439T (pt) | 2017-11-15 | 2023-05-15 | Array Biopharma Inc | Inibidores de kras g12c |
| RU2020123151A (ru) | 2017-12-19 | 2022-01-20 | Мерк Патент Гмбх | Антагонисты tlr7/8 и их применение |
| TW201942115A (zh) | 2018-02-01 | 2019-11-01 | 美商輝瑞股份有限公司 | 作為抗癌藥之經取代的喹唑啉和吡啶並嘧啶衍生物 |
-
2019
- 2019-11-08 RS RS20241331A patent/RS66280B1/sr unknown
- 2019-11-08 PT PT198428484T patent/PT3735299T/pt unknown
- 2019-11-08 AR ARP190103302A patent/AR117194A1/es unknown
- 2019-11-08 ES ES19842848T patent/ES3004042T3/es active Active
- 2019-11-08 CA CA3087089A patent/CA3087089C/en active Active
- 2019-11-08 FI FIEP19842848.4T patent/FI3735299T3/fi active
- 2019-11-08 MY MYPI2021002582A patent/MY196726A/en unknown
- 2019-11-08 PE PE2021000682A patent/PE20211504A1/es unknown
- 2019-11-08 SG SG11202103298QA patent/SG11202103298QA/en unknown
- 2019-11-08 US US16/679,104 patent/US11236068B2/en active Active
- 2019-11-08 SI SI201930862T patent/SI3735299T1/sl unknown
- 2019-11-08 MX MX2021005428A patent/MX2021005428A/es unknown
- 2019-11-08 PL PL19842848.4T patent/PL3735299T3/pl unknown
- 2019-11-08 BR BR112021008986-1A patent/BR112021008986A2/pt unknown
- 2019-11-08 AU AU2019377130A patent/AU2019377130B2/en active Active
- 2019-11-08 CN CN201980026181.6A patent/CN112105419B/zh active Active
- 2019-11-08 EP EP19842848.4A patent/EP3735299B1/en active Active
- 2019-11-08 TW TW111140273A patent/TWI883352B/zh active
- 2019-11-08 HR HRP20241581TT patent/HRP20241581T1/hr unknown
- 2019-11-08 CN CN202410280860.9A patent/CN118084866A/zh active Pending
- 2019-11-08 UA UAA202101478A patent/UA127930C2/uk unknown
- 2019-11-08 LT LTEPPCT/US2019/060578T patent/LT3735299T/lt unknown
- 2019-11-08 CN CN202410281087.8A patent/CN118084870A/zh active Pending
- 2019-11-08 CN CN202410281112.2A patent/CN118084868A/zh active Pending
- 2019-11-08 PE PE2025003077A patent/PE20260440A1/es unknown
- 2019-11-08 DK DK19842848.4T patent/DK3735299T3/da active
- 2019-11-08 IL IL311187A patent/IL311187B1/en unknown
- 2019-11-08 KR KR1020257000144A patent/KR20250012188A/ko active Pending
- 2019-11-08 CN CN202410280943.8A patent/CN118084867A/zh active Pending
- 2019-11-08 CR CR20210229A patent/CR20210229A/es unknown
- 2019-11-08 SM SM20240487T patent/SMT202400487T1/it unknown
- 2019-11-08 IL IL282916A patent/IL282916B2/en unknown
- 2019-11-08 HU HUE19842848A patent/HUE069365T2/hu unknown
- 2019-11-08 WO PCT/US2019/060578 patent/WO2020097537A2/en not_active Ceased
- 2019-11-08 MA MA51530A patent/MA51530B1/fr unknown
- 2019-11-08 KR KR1020207024122A patent/KR102587544B1/ko active Active
- 2019-11-08 JP JP2020542808A patent/JP6941241B2/ja active Active
- 2019-11-08 EP EP24198360.0A patent/EP4483881A3/en active Pending
- 2019-11-08 TW TW108140719A patent/TWI784209B/zh active
- 2019-11-08 KR KR1020237033977A patent/KR102751492B1/ko active Active
-
2021
- 2021-05-04 CL CL2021001171A patent/CL2021001171A1/es unknown
- 2021-05-07 MX MX2025002980A patent/MX2025002980A/es unknown
- 2021-05-07 MX MX2025002979A patent/MX2025002979A/es unknown
- 2021-05-07 MX MX2025002975A patent/MX2025002975A/es unknown
- 2021-05-07 MX MX2024008118A patent/MX2024008118A/es unknown
- 2021-05-07 PH PH12021551065A patent/PH12021551065A1/en unknown
- 2021-05-07 CO CONC2021/0005987A patent/CO2021005987A2/es unknown
- 2021-07-15 JP JP2021116809A patent/JP7374960B2/ja active Active
- 2021-12-17 US US17/644,993 patent/US12084429B2/en active Active
-
2022
- 2022-03-01 AU AU2022201413A patent/AU2022201413B9/en active Active
- 2022-03-22 CL CL2022000698A patent/CL2022000698A1/es unknown
-
2023
- 2023-10-25 JP JP2023183500A patent/JP7579414B2/ja active Active
-
2024
- 2024-02-13 AU AU2024200904A patent/AU2024200904B2/en active Active
- 2024-06-18 US US18/747,054 patent/US20250059163A1/en active Pending
- 2024-10-25 JP JP2024187827A patent/JP2025026853A/ja active Pending
-
2025
- 2025-10-20 IL IL324078A patent/IL324078A/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL282916A (en) | Compressed ring compounds | |
| IL280797A (en) | fused ring compounds | |
| IL282984A (en) | bicyclic compounds | |
| ZA202007956B (en) | Compounds | |
| GB201805174D0 (en) | Compounds | |
| GB201801355D0 (en) | Compounds | |
| GB2570474B (en) | Region fusing | |
| AU201814138S (en) | Snap Ring | |
| CA190818S (en) | Ring | |
| GB201811169D0 (en) | New compounds | |
| GB201810668D0 (en) | New compounds | |
| GB201810669D0 (en) | New compounds | |
| GB201803340D0 (en) | Compounds | |
| GB201801130D0 (en) | Compounds | |
| CA185767S (en) | Ring | |
| IL270966A (en) | Fused bicyclic compounds | |
| CA189948S (en) | Ring | |
| PH32019000869S1 (en) | Ring | |
| IL258942A (en) | Talit composed ring | |
| HK40026053A (en) | Fused bicyclic compounds | |
| GB201817634D0 (en) | New compounds | |
| GB201813681D0 (en) | New compounds | |
| GB201815229D0 (en) | Sealing ring | |
| GB201805945D0 (en) | New compounds | |
| GB201804745D0 (en) | New compounds |